Product Details
Alternative Name: | Epidermal growth factor receptor, EGFR, HER-1 |
|
Clone: | 13G8 |
|
Host: | Mouse |
|
Isotype: | IgG1 |
|
Immunogen: | Synthetic peptide corresponding to aa 1165-1186 of EGF receptor (epidermal growth factor receptor) conjugated to KLH. |
|
UniProt ID: | P00533 |
|
Species reactivity: | Human, Mouse
|
|
Specificity: | Recognizes the C-terminus of the EGF receptor (aa 1165-1186). Recognition is independent of phosphorylation of Tyr1173. |
|
Applications: | ELISA, ICC, IP, WB Luminex
|
|
Recommended Dilutions/Conditions: | Immunocytochemistry (0.1-1µg/ml) Western Blot (1µg/ml for HRPO/ECL detection; recommended blocking buffer CPPT: 10mM TRIS-HCl, pH 7.4, 0.5% (w/v) casein, 1% (w/v) PEG 4,000, 1% (w/v) polyvinylpyrrolidone, 0.1% (v/v) Tween 20, 150mM sodium chloride) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Positive Control: | Included. (Prod. No. ALX-840-030) |
|
Purity Detail: | Thiophilic adsorption and size exclusion chromatography purified. |
|
Formulation: | Lyophilized from 1ml of 2x PBS containing 0.09% sodium azide, PEG, and sucrose. |
|
Reconstitution: | Reconstitute with 1ml water (15 minutes at room temperature). |
|
Use/Stability: | Stable at -80°C up to 1 year, at 4°C up to 3 months. |
|
Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and freeze in liquid nitrogen. |
|
Shipping: | Blue Ice |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary: S. Brundu, et al.; EMBO Mol. Med.
15, e16104 (2023),
Abstract;
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers: S. Misale, et al.; Nat. Commun.
6, 8305 (2015),
Application(s): Immunoblot Analysis,
Abstract;
Full Text
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells: S. Lamba, et al.; Cell Rep.
8, 1475 (2014),
Application(s): Western Blotting,
Abstract;
Full Text
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer: S. Misale, et al.; Nature
486, 532 (2012),
Abstract;
Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor: A. Weyergang, et al.; Biochem. Pharmacol.
74, 226 (2007),
Application(s): Western blot,
Abstract;